Arcutis Biotherapeutics, Inc. (ARQT) Investor Relations Documents

Arcutis Biotherapeutics, Inc. (ARQT) investor relations documents from the company's IR site: 8 presentations, 28 press releases; latest deck 2026-06-12. Read in-app with summaries. First-party data.

Arcutis June 2026 Corporate Presentation: Arcutis Biotherapeutics' June 2026 corporate presentation highlights $372.1 million in 2025 net revenue and a 2026 sales guidance of $480–$495 million.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-07Press releaseArcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-08-05Press releaseArcutis Announces Second Quarter 2026 Financial Results and Provides Business Update
2026-07-16Press releaseJul 16, 2026 Arcutis Expands Board of Directors with Appointment of Chris Peetz Read More
2026-07-15Press releaseJul 15, 2026 Arcutis to Report Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026 Read Mor
2026-07-08Press releaseJul 08, 2026 FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Read M
2026-07-02Press releaseArcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-06-30Press releaseJun 30, 2026 Arcutis Launches New Virtual Health Platform Supporting Access to Care for Individuals Living with C Read M
2026-06-29Press releaseJun 29, 2026 FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Chil Read M
2026-06-12PresentationArcutis June 2026 Corporate Presentation
2026-06-05Press releaseArcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-06-03Press releaseJun 03, 2026 New Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital Read Mo
2026-05-26Press releaseMay 26, 2026 Arcutis Management to Present at Goldman Sachs 47th Annual Global Healthcare Conference Read More
2026-05-06DocumentArcutis Announces First Quarter 2026 Financial Results and Provides Business Update
2026-05-06Press releaseArcutis First Quarter 2026 Financial Results & Business Update
Press releaseMay 06, 2026 Arcutis Announces First Quarter 2026 Financial Results and Provides Business Update Read More
2026-04-27Press releaseApr 27, 2026 Arcutis Submits Supplemental New Drug Application to the FDA for ZORYVE® (roflumilast) Cream 0.05% t Read M
2026-04-22Press releaseApr 22, 2026 Arcutis’ ZORYVE® (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatolo Read M
PresentationApr 15, 2026 Arcutis to Report First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026 Read More
2026-03-31Press releaseMar 31, 2026 Arcutis Management to Present at the 25th Annual Needham Virtual Healthcare Conference Read More
2026-03-28Press releaseMar 28, 2026 Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Toda Read M
2026-03-18Press releaseMar 18, 2026 Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters a Read M
2026-03-10Press releaseMar 10, 2026 Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE® (roflumila Read M
2026-03-05Press releaseMar 05, 2026 Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Su Read M
2026-03-03Press releaseMar 03, 2026 Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Voluntee Read M
2026-02-27Press releaseFeb 27, 2026 Arcutis Management to Present at TD Cowen’s 46th Annual Health Care Conference Read More
2026-02-25PresentationArcutis Fourth Quarter 2025 Financial Results & Business Update
2026-02-25Press releaseArcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
2026-02-25Press releaseFeb 25, 2026 Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update Read Mor
2026-02-02Press releaseFeb 02, 2026 Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE® (roflumila Read M
2026-01-26Press releaseJan 26, 2026 Arcutis Biotherapeutics, Inc. Announces Termination of Promotion Agreement with Kowa Read More
2026-01-22Press releaseJan 22, 2026 Arcutis to Report Fourth Quarter and Full Year 2025 Financial Results and Present at Upcoming Invest Read M
2026-01-12Press releaseJan 12, 2026 Arcutis Highlights 2026 Strategic Priorities and Anticipated Milestones Read More
PresentationOct 28, 2025 Arcutis Outlines Strategy for Driving Sustainable Growth and Announces Third Quarter 2025 Financial Read Mo
2025-10-27DocumentArcutis Announces Third Quarter 2025 Financial Results and Provides Business Update
2025-10-27DocumentArcutis Investor Day and Third Quarter 2025 Financial Results
PresentationSep 29, 2025 Arcutis Biotherapeutics to Host Virtual Investor Day and Report Third Quarter 2025 Financial Results Read M
2025-08-06DocumentArcutis Second Quarter 2025 Financial Results & Business Update
2025-08-06PresentationArcutis Announces Second Quarter 2025 Financial Results and Provides Business Update
PresentationAug 06, 2025 Arcutis Announces Second Quarter 2025 Financial Results and Provides Business Update Read More
PresentationJul 23, 2025 Arcutis to Report Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025 Read Mor

ARQT overview · ARQT earnings · ARQT financials · ARQT KPIs · ARQT documents · ARQT ownership · ARQT peers

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.